PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma

Wanglong Qiu,¹ Frank Schönlbe,¹ Xiaojun Li,¹ Daniel J. Ho,¹ Lanny G. Close,¹ Spiros Manolidis,¹ Boyce P. Bennett,² and Gloria H. Su¹,²

Abstract

Purpose: Recent studies have reported high frequencies of somatic mutations in the phosphatidylinositol-3-kinase catalytic α (PIK3CA) gene in several human solid tumors. Although gene amplifications of PIK3CA have been reported in head and neck squamous cell carcinoma (HNSCC), small mutation of the gene has not been evaluated in HNSCC previously. In this study, we examined the mutation frequency of PIK3CA in HNSCC.

Experimental Design: More than 75% of the somatic mutations of PIK3CA are clustered in the helical (exon 9) and kinase domains (exon 20). To investigate the possible role of PIK3CA in HNSCC tumorigenesis, exons 1, 4, 5, 6, 7, 9, and 20 of the gene were analyzed by direct genomic DNA sequencing in 38 HNSCC specimens.

Results: We identified four missense mutations in the seven exons of PIK3CA from 38 HNSCC specimens (11%). Three of the four mutations (i.e., H1047R, E542K, and E545K) have been previously reported as hotspot mutations. The remaining novel mutation, Y343C, is identified at exon 4 nucleotide 1028 A → G. Three of the four mutations were shown to be somatic, whereas the fourth mutation (H1047R) was identified in a cell line. Interestingly, three of the four mutations identified were in pharyngeal cancer samples.

Conclusions: These data provide evidence that oncogenic properties of PIK3CA contribute to the carcinogenesis of human head and neck cancers, especially in pharyngeal cancer. A specific kinase inhibitor to PIK3CA may potentially be an effective therapeutic reagent against HNSCC or pharyngeal cancer in particular.

Authors’ Affiliations: Departments of ¹Otolaryngology/Head and Neck Surgery and ²Pathology, Columbia University College of Physicians and Surgeons, New York, New York

Received 10/4/05; revised 11/10/05; accepted 12/15/05.

Grant support: National Cancer Institute Temin Award grant CA95434 and National Cancer Institute grant R01 CA109525.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Gloria H. Su, Department of Otolaryngology/Head and Neck Surgery, Columbia University College of Physicians and Surgeons, 1130 St. Nicholas Avenue, ICRC10-04, New York, NY 10032. Phone: 212-851-4624; E-mail: gs2157@columbia.edu.

© 2006 American Association for Cancer Research.

doi:10.1158/1078-0432.CCR-05-2173

Materials and Methods

Tissue samples and cell lines. Eight HNSCC cell lines (RPMI 2650, A-253, SW579, Detroit 562, FADU, CAL 27, SCC-15, and SCC-25) were purchased from the American Type Culture Collection (Rockville, MD). The cell lines were maintained as recommended by the American Type Culture Collection.

Thirty frozen primary tumor samples and their corresponding match normal muscle specimens were obtained from the Tumor Bank facility of the Herbert Irving Comprehensive Cancer Center and Department of
PCR product derived independently from the original template. The mutation was then further verified by sequencing of a second reverse direction to confirm the mutation using the reverse PCR primers. Genetic alterations in the target were subsequently sequenced in the published sequencing primers (13). All samples found to have a facility of Columbia University Medical Center using previously done with ABI’s 3100 capillary automated sequencers at the DNA facility of Columbia University Medical Center using previously published sequencing primers (13). All gene sequencings were done according to the manufacturer’s instructions.

Exons 1, 4, 5, 6, 7, 9, and 20 of the PIK3CA gene were analyzed by PCR amplification of genomic DNA and PCR product direct sequencing. Genomic DNAs (40 ng per sample) were amplified with primers covering the entire coding region and the exon/intron boundaries of the desired exons (PIK3CA-E9F, 5'-CTGTAACCCAGGGAAGAA-3'; PIK3CA-E9R, 5'-GCATTGAAATGCGCACTACCA-3'; PIK3CA-E9FS, 5'-TCAGACGGGAAAAATATGACA-3'; ref. 13). All gene sequencings were done with ABI’s 3100 capillary automated sequencers at the DNA facility of Columbia University Medical Center using previously published sequencing primers (13). All samples found to have a genetic alteration in the target were subsequently sequenced in the reverse direction to confirm the mutation using the reverse PCR primers (13). The mutation was then further verified by sequencing of a second PCR product derived independently from the original template.

Results

A novel sequence identified similar to PIK3CA. Although sequencing for mutations using primers we had designed for exon 9, we were surprised to find an alteration at nucleotide 1634 A → C (E545A) in all the cases (Figs. 1 and 2). However, this nucleotide change of PIK3CA A1634C (E545A) always coexisted with another alteration of G → C at nucleotide 1658 and a base deletion at nucleotide 1659 (Fig. 1). Subsequent sequencing analyses of the matching normal tissue specimens revealed that the same nucleotide changes occurred in both tumor and normal tissues (data not shown). This unusual result led us to blast search this PCR fragment (410-bp long) in the Genbank. We found two genomic DNA clones that contain fragments that are 97% (401 of 410) homologous to the exon 9 and its flanking intronic sequences. These two clones are located at chromosome 22q11.2 cat eye syndrome region (gi 5931525) and at chromosome 16 (gi 28913054; Fig. 2; data not shown). Further comparisons of the sequences using the BLAST search revealed that both genomic clones on chromosomes 22 and 16 contain sequences highly homologous to the exons 9, 11 to 13, and partial exon 10 of the PIK3CA gene (data not shown). An automatic computational analysis using the GNOMON gene prediction method predicted a protein that can be transcribed and translated from the chromosome 22 clone. The predicted protein (gi 51475436) is similar to the helical domain of the PIK3CA protein. However, this sequence homologue is likely to be a pseudogene because no RNA transcripts of the predicted protein can be detected by reverse transcription-PCR (data not shown).

This sequence homologue was probably not reported by previous publications because its detectability depends highly on primer designs. When we moved the PCR primer sites, used the primers published in the study by Samuels et al. (13), or increased the stringency of our PCR condition, all the nucleotide alterations, including the so-called PIK3CA A1634C (E545A) “mutation” disappeared. We concluded that the A1634C (E545A) “mutation” observed in our hands was an artifact created by interferences from the sequence homologue.

PIK3CA is activated by small mutation in HNSCC. Four missense mutations of the PIK3CA gene were identified in the 38 HNSCC specimens (Fig. 3; Table 1): two of the mutations were in the exon 9 (E545K and E542K), one was in the exon 20 (H1047Y), and one was in the exon 4 (Y343C). None of these mutations was detected in the corresponding normal tissues except for the H1047Y mutation, which was identified in HNSCC cell line Detroit 562. Three of the four PIK3CA missense mutations (E545K, E542K, and H1047R) are previously described hotspot mutations (13). Functional studies showed that PI3K carrying any one of the three hotspot mutations is able to induce transformation in cultures of chicken embryo fibroblasts, and that the transforming activity of the mutant is correlated with increased lipid kinase activity and activation of the Akt signaling pathway (13, 19). The mutation in the exon 4 nucleotide 1028 A → G, which leads to...
alteration at codon 343 TAC (Y) → TGC(C), has not been described before (Fig. 3).

Two other nucleotide alterations were also detected in the exonic regions of the PIK3CA gene (Table 1). One alteration, located at the exon 6 nucleotide 1173 A → G [codon 391 ATA (ILE) → ATG (Met)] was found in six HNSCC tumor specimens. This nucleotide alteration was also detected in the six matching normal tissues. A search of the SNP database revealed that A1173G is a known SNP (rs2230461) that has been validated by multiple PCR reactions and genotype data. Thus, we conclude that this germ line alteration represents a non–disease-causing polymorphism of PIK3CA. Another exonic

![Fig. 2. Alignment of a PCR fragment of the PIK3CA gene containing exon 9 and its flanking intronic sequences with a human genomic DNA clone located at chromosome 22q11.2 cat eye syndrome region (gi 5931525). The alignment shows that the homology between the two pieces of nucleotide sequences is 97% (401 of 410). Arrows mark the three nucleotide differences located inside the exon 9 coding region (in top cases). The PCR primers designed by us (PIK3CA-E9F and PIK3CA-E9R) and Samuel et al. (hCT1640694-Ex9F and hCT1640694-Ex9R) are underlined.](image)

![Fig. 3. PIK3CA mutations found in HNSCC. Three of the four mutations (E545K, E542K, and Y343C) were confirmed to be somatic in sporadic HNSCC. The H1047R mutation was found in a HNSCC cell line.](image)
alteration was also deemed a polymorphism because it occurred at exon 5 C1143G (P381P) without resulting in an amino acid change and was observed in both the tumor and normal samples of one tongue cancer patient. All of the polymorphisms observed in the intronic regions flanking the seven exons of PIK3CA examined in this study are listed in Table 2. These polymorphisms are unlikely to cause significant changes in the function of PIK3CA.

Table 1. Nucleotide alterations within the coding exons of PIK3CA identified in 38 HNSCC specimens

<table>
<thead>
<tr>
<th>Cases</th>
<th>Exon</th>
<th>Nucleotide</th>
<th>Amino acid</th>
<th>Present in normal tissue</th>
<th>Tumor site (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Detroit 562</td>
<td>20</td>
<td>A3140G</td>
<td>H1047R</td>
<td>NA</td>
<td>Pharynx (1)</td>
</tr>
<tr>
<td>102T</td>
<td>9</td>
<td>G1624A</td>
<td>E542K</td>
<td>No</td>
<td>Oropharynx (1)</td>
</tr>
<tr>
<td>109T</td>
<td>9</td>
<td>G1633A</td>
<td>E545K</td>
<td>No</td>
<td>Hypopharynx (1)</td>
</tr>
<tr>
<td>182T</td>
<td>4</td>
<td>A1028G</td>
<td>Y343C</td>
<td>No</td>
<td>Tongue (1)</td>
</tr>
<tr>
<td>80T</td>
<td>5</td>
<td>C1143G</td>
<td>P381P</td>
<td>Yes</td>
<td>Tongue (1)</td>
</tr>
<tr>
<td>6 cases</td>
<td>6</td>
<td>A1173G</td>
<td>I391M</td>
<td>Yes</td>
<td>Pharynx (2) oral (2) Larynx (1) neck (1)</td>
</tr>
</tbody>
</table>

NOTE: The nucleotide alterations are described according to the cDNA sequence with Genbank accession no. NM_006218. Abbreviation: NA, not available.

Discussion

The mutation frequency of PIK3CA has been reported at 32% in colon cancer, ~4% to 25% in gastric cancer, 8% to 40% in breast cancer, 5% to 27% in brain cancer, 4% in lung cancer, and 4% to 7% in ovarian cancer (13, 16–18, 25). In the present study, we report 11% (4 of 38) of PIK3CA mutations in sporadic HNSCC. Interestingly, three of the four cases with mutations are from the same organ site, pharynx (Table 1). Cancer of the pharynx is the ninth most common cancer worldwide (27). It is characterized as the following subsites: posterior pharynx, hypopharynx, and lateral pharyngeal walls. A total of six pharyngeal squamous cell carcinoma cases were examined in this study, suggesting that as high as 50% (3 of 6) of pharyngeal tumor samples may harbor PIK3CA mutations. These data are supported by a previous report that showed chromosome 3q26 is amplified in 100% of nasopharyngeal carcinoma (22). However, from the present study, we are unable to conclude the exact mutational frequency of PIK3CA in pharyngeal carcinomas and comment on which subtype of pharyngeal carcinomas (nasopharynx, oropharynx, and hypopharynx) is targeted for PIK3CA mutation. Among our six pharyngeal samples, there was one oropharyngeal cancer sample, one hypopharyngeal cancer, and four that were not subtyped. More studies with larger sample sizes and various pharyngeal subtypes are necessary to further investigate these potentials.

Gene amplification is a more commonly observed mechanism of oncogene activation in HNSCC than small genetic mutation. Cyclin D1 gene amplification has been observed in ~34% to 37% of HNSCC (28, 29). EGF receptor gene amplification has been reported in 7% to 19% of HNSCC (30–32). In contrast, RAS mutation is relatively rare in HNSCC compared with other solid cancers: ~6% in HNSCC versus 99% in pancreatic cancer and 37% to 47% in colorectal cancer (33–39). Amplification of chromosome 3q26 is frequently observed in HNSCC and is linked to tumor progression and negatively correlated with clinical outcome (40–42). Gene amplification and overexpression of PIK3CA are observed in low to moderate dysplastic cases, but their increased frequencies are associated with transition to invasive cancer (21, 23). Here, we showed that gene amplification is not the only mechanism to activate PIK3CA in HNSCC. Small mutation and gene amplification both contribute to the activation of PIK3CA in HNSCC.

In summary, we report missense mutations of the PIK3CA gene in HNSCC (4 of 38, 11%). Among the four cases identified here, the Y343C mutation, which is located at PIK3CA exon 4 nucleotide 1028 A → G, is novel and has not been described in previous studies. Although the physiologic significance of the novel mutation Y343C, which is located within the PIK3CA C2 domain, is not known, it has been shown that the C2 domain in the class IB PI3K interacts primarily with the helical domain and also interacts with the linker segment before the Ras-binding domain and with the COOH-terminal lobe of the catalytic domain (43). The C2 domain is often involved in Ca2+-dependent mechanisms of cell signaling, such as the activation of PI3K by membrane-bound ligands, with the exception of the C2A domain, which has been found to be involved in Ca2+-independent phospholipid binding. By analogy, with enzymes like protein kinase C and cytosolic phospholipase A2, the C2 domain of class IB PI3K might participate in Ca2+-independent phospholipid binding (43). Because mutations found in the C2 domain account for 7% of total
PIK3CA mutations found in a study of 396 cancer samples (13), it will be worthwhile to determine the exact function of the C2 domain of class 1A PI3K in future studies. The other three are hotspot mutations (E545K, E542K, and H1047R), and all were found in pharyngeal cancer patients. The smoking histories of the mutated patients are unknown. We did not find any significant correlation of the PIK3CA gene mutation to the gender or age of the patients.

Here, we also report the discovery of a PIK3CA homologue. This homologue is almost identical to the exons 9, 11 to 13, and partial exon 10 of the PIK3CA gene and can be found on both chromosomes 16 and 22. However, we think that this sequence homolog is likely to be a pseudogene because no RNA transcripts of the predicted protein can be detected by reverse transcription-PCR. In our study, interferences from this sequence homologue had caused confusions by creating nucleotide alterations, including the so-called PIK3CA A1634C (E545A) “mutation” (Figs. 1 and 2), which subsequently vanished with better primer designs and more stringent PCR conditions. Intriguingly, this A1634C (E545A) mutation has been previously reported in human cancers by two publications. One study described 11 cases with the A1634C (E545A) mutation out of 73 hepatocellular carcinomas (15). More recently, this exact mutation was reported to contribute (E545A) to 21 of 24 hepatocellular carcinomas (15). Recently kinase inhibitors such as Gleevec (Imatinib), Herceptin (Trastzumab), and Iressa (Gefitinib) have been successfully developed for therapies in some cancer types (45). Because amplification and overexpression of the PIK3CA gene locus is an early oncogenic event of HNSCC tumorigenesis and is also correlated to invasion (21, 23), abrogation of its oncogenic activities may conceivably slow or stop tumor progression. It is believed that such a selective small-molecule inhibitor against PIK3CA would have tremendous potential as a novel cancer chemotherapeutic for HNSCC (46). Our findings further supports PIK3CA as an important potential target in head and neck cancer for pathway-specific, kinase inhibitor-based therapies.

References
31. Ishiyama Y, Toniyama M, Oguchi N, et al. Gene amplification and overexpression of EGFr receptor in...


PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma

Wanglong Qiu, Frank Schönleben, Xiaojun Li, et al.


Updated version  Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/12/5/1441

Cited articles  This article cites 45 articles, 14 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/12/5/1441.full#ref-list-1

Citing articles  This article has been cited by 19 HighWire-hosted articles. Access the articles at:
http://clincancerres.aacrjournals.org/content/12/5/1441.full#related-urls

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.